Stewardship Cuts IV Treatment for Paediatric Bone Infections
A hospital-based antimicrobial stewardship program (ASP) using post-prescription review and feedback (PPRF) significantly decreased intravenous (IV) antibiotic duration, length of hospital stay, and reliance on third-generation cephalosporin in paediatric bone and joint infections over 5 years.
METHODOLOGY:
This single-centre, quasi-experimental study evaluated the effect of a PPRF-based multifaceted ASP on antibiotic use, treatment duration, and length of hospital stay in paediatric acute haematogenous bone and joint infections (AH-BJIs).
This study included 285 children: 60 in the pre-ASP (2015-2016; mean age, 1.9 years; 50% boys) and 225 in the post-ASP (2017-2023; mean age, 2.9 years; 67.5% boys).
Data on demographics, clinical features, microbiology, and treatment were collected from electronic medical records.
Primary outcomes were parenteral/oral antibiotic duration, length of hospital stay, and clinical outcomes (sequelae, readmission, and mortality).
TAKEAWAY:
The median IV antibiotic duration and length of hospital stay in children with AH-BJIs were both significantly reduced after ASP implementation, dropping from 8.5 (interquartile range [IQR], 7.0-12.0) to 7 (IQR, 4.5-8.0) days and from 8.5 (IQR, 7.0-11.0) to 7 (IQR, 5.0-9.0) days, respectively (P < .001 for both).
Post-2020, broad-spectrum antibiotic use significantly declined, with third-generation cephalosporin use fell from 81% to 10% in children aged 5 years or younger and cloxacillin use declined by 60.0% in children older than 5 years in favour of narrower spectrum cefazolin (P < .001 for both).
Methicillin-susceptible Staphylococcus aureus was the most common pathogen (22.8%), followed by Kingella kingae (10.9%), which was found in only children younger than 4 years. Blood cultures were positive in 29.3% of cases.
Among 52 children with soft-tissue/subperiosteal abscesses (46 occurring post-ASP), the median oral antibiotic duration was 41 days, with total treatment lasting 47 days; the ASP maintained safety, with no increase seen in sequelae (6.3% overall), readmissions (3.3% in the pre-ASP vs 3.6% in the post-ASP), and mortality (0%).
IN PRACTICE:
"After ASP implementation, the length of parenteral antibiotic treatment, length of hospital stay, and 3rd generation cephalosporin use in children with AH-BJI were reduced safely," the authors wrote.
SOURCE:
This study was led by Aina Font, Pharmacy Department, Consorci Hospitalari de Vic, Vic, Spain. It was published online on June 18, 2025, in the European Journal of Pediatrics.
LIMITATIONS:
This single-centre study had several limitations, such as the unbalanced sample size and inclusion of neonates, which may have affected generalisability; the findings based on local epidemiology may not apply to other settings. This study did not evaluate treatment days per 1000 admissions, cost-effectiveness, COVID-19 impact, diagnostic advances, and staff turnover effects, nor it systematically monitor prescriber adherence or satisfaction with the stewardship program.
DISCLOSURES:
No funding was secured for this study. The authors declared having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
Report: Autopsy found Cincinnati Bearcats offensive lineman Jeremiah Kelly had heart condition
CINCINNATI (AP) — A Cincinnati Bearcats offensive lineman who died unexpectedly in April had a heart condition, an autopsy has found. ESPN reported on Tuesday that Jeremiah Kelly, an early enrollee who took part in spring practices with the Bearcats, had 'cardiac hypertrophy,' a thickening of the heart muscles. He was found unresponsive at his residence on April 22. 'The Bearcats football family is heartbroken by the sudden loss of this outstanding young man,' coach Scott Satterfield said in April. 'In the short time Jeremiah has spent with our team, he has made a real impact, both on the field and in our locker room. My prayers are with the Kelly family and those who had the pleasure of knowing Jeremiah.' A freshman from Avon, Ohio, Kelly was a 6-foot-3, 320-pound offensive lineman who helped Avon High School to a 16-0 record and a state championship in 2024. ___ AP college football: and
Yahoo
31 minutes ago
- Yahoo
Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for Rare Diseases
BOSTON, July 22, 2025 /PRNewswire/ -- In a new article published in Value in Health, researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), collaborated with Novartis to examine how HEOR is transforming the evaluation and access pathways for cell and gene therapies (CGTs) for rare diseases. As CGTs move from experimental to increasingly approved treatments for rare diseases, health systems face urgent questions about how to evaluate, reimburse, and scale their access equitably. In their article, the authors spotlight five key HEOR innovation areas that are enhancing the generation of real-world evidence (RWE), supporting novel endpoints, and shaping future models of affordability and access. Because of small patient populations, heterogeneous disease presentations, a lack of effective alternative treatments, and hence, ethical concerns, gold standard randomized double-blind controlled clinical trials are often not suitable for establishing efficacy and safety for CGT treatments. Consequently, traditional economic models are not able to capture the holistic value of CGTs, given that the true benefits associated with such treatments are subject to a much longer time outside of the trial periods. For example, for patients with rare hereditary genetic disorders, timely access to CGTs can yield real differences in meaningful gains in life years. To address these challenges, researchers are increasingly relying on innovations in HEOR to inform proper clinical and economic evaluation of CGTs. An Analysis Group team led by Managing Principal Min Yang, Manager Su Zhang, and affiliate Lou Garrison collaborated with researchers from Novartis, led by Dr. Walter Toro, to examine the advancements in the evaluation of CGTs made possible by HEOR innovations, including the design and collection of long-term real-world data (RWD) for CGT efficacy extrapolation, justification for use of novel endpoints, integration of patient voices and preferences, and application of sophisticated statistical methodology, sometimes augmented with artificial intelligence (AI) or natural language processors. These advances are reflected in regulators' and health technology assessment (HTA) agencies' growing openness to the acceptance of RWE and patient-centered endpoints in their evaluations, marking a shift from traditional standards that may not suit CGTs. The authors note that emerging value assessment frameworks and novel reimbursement models offer solutions and adaptability to decision makers with enhanced ability to manage health equity and affordability.
Forbes
34 minutes ago
- Forbes
Pretending We Don't Owe Money Doesn't Mean We Don't Owe Money
DORCHESTER - APRIL 05: Dominique Entzminger, a physician assistant of family medicine, wears a ... More stethoscope during an examination at the Codman Square Health Center April 5, 2006 in Dorchester, Massachusetts. State lawmakers approved a health care reform bill March 4 that would make Massachusetts the first state in the nation to require all its citizens have some form of health insurance. Governor Mitt Romney is scheduled to sign the bill next week. (Photo by) Markets always have their say. This was recently acknowledged, at least implicitly, by a federal judge in Texas. Judge Sean Jordan ruled against a Biden-era decree from the Consumer Financial Protection Bureau that tens of billions worth of medical debt be excluded from credit reports. Jordan should be cheered for his ruling. But not just because it signals rationality on his part. Jordan most rates credit for protecting the health of consumers. Think about it. As evidenced by the $49 billion worth of medical debt that the CFPB wanted removed from the credit reports of 15 million people, there's a very real need for medical-related care in the United States. Put another way, no one runs up medical debt just because. Which speaks to the foolhardy nature of the initial CFPB decree. Imagine if it had held such that debt related to healthcare could be left off credit reports. If so, it would on its face increase the incentive among those with medical debt to cease paying it, all based on the presumption that a failure to keep current on debts wouldn't shrink one's credit score. It might seem harmless to some at first glance, but for the problem that unpaid bills don't just happen. There's a market reaction to a failure to pay. Specifically, a rising tendency for medical debts to go unpaid would most certainly result in reduced availability of medical care for all would-be patients. What else would doctors and medical professionals be expected to do? If going forward the pretense will be that medical debt doesn't exist on the matter of credit reports, logic dictates that medical care on credit would have to shrink to reflect the decree. Which is just a comment that when governments err to protect a few, or even millions, the burden is suffered by exponentially more. If there's no punishment in a credit sense for ignoring certain bills, then it only makes sense that would-be patients will similarly be ignored to the extent that their capacity to pay isn't trusted as much thanks to a few, or many, bad apples. And it won't just be limited to medical care. See yet again how much in the way of debt that the CFPB wanted erased from credit reports. Stated simply, $49 billion isn't exactly a tiny number. Which means that if it can no longer reflect on credit reports, the worth of credit reports themselves will decline. It's the housing equivalent of a home appraisal, albeit one that lacks crucial information like square footage, bedroom and bathroom count, along with whether the house has central air conditioning. Would you buy such a house sight unseen? Hopefully the question answers itself. Ideally it also explains the importance of credit reports reflecting reality, as opposed to a truncated version of the latter. Absent the truth, how can any provider of goods and services (not just a doctor or a hospital) confidently provide them on a to-be-paid basis? Which is a reminder of the point made at the beginning of this piece, that markets always have their say. It's worth remembering as states contemplate doing locally what Judge Jordan stood athwart nationally. That which obscures reality doesn't alter reality, which means statewide decrees meant to mirror the CFPB's attempted one will not just harm consumer health, but their ability to attain goods and services more broadly.
